Estados Unidos - inglês - NLM (National Library of Medicine)

lake erie medical dba quality care products llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 16 mg

Estados Unidos - inglês - NLM (National Library of Medicine)

physicians total care, inc. - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - exalgo is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. limitations of use exalgo is not for use: - as an as-needed (prn) analgesic - for pain that is mild or not expected to persist for an extended period of time - for acute pain - for postoperative pain. exalgo is contraindicated in: - opioid non-tolerant patients. fatal respiratory depression could occur in patients who are not opioid tolerant. - patients with significant respiratory depression - patients with acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment - patients with known or suspected paralytic

Estados Unidos - inglês - NLM (National Library of Medicine)

purdue pharma lp - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 1 mg in 1 ml - dilaudid injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. dilaudid-hp injection is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day. or an equianalgesic dose of another opioid for one week or longer. patients must remain on around-the-clock opioids while administering dilaudid-hp. limitations of use: because of the risks of addiction, abuse, and misuse with opioids, even at recommen

Estados Unidos - inglês - NLM (National Library of Medicine)

specgx llc - hydromorphone hydrochloride (unii: l960up2krw) (hydromorphone - unii:q812464r06) - hydromorphone hydrochloride 8 mg - exalgo is indicated for the management of pain in opioid-tolerant patients severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. patients considered opioid tolerant are those who are receiving, for one week or longer, at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. limitations of use - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve exalgo for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. because of the risks

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

hameln pharma pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: citric acid monohydrate; sodium chloride; hydrochloric acid; sodium citrate dihydrate; water for injections; sodium hydroxide - hydromorphone-hameln and hydromorphone-hameln-hp injections are indicated for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated or are otherwise inappropriate to provide sufficient management of pain.

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

as kalceks - hydromorphone hydrochloride - solution for injection/infusion - hydromorphone

Irlanda - inglês - HPRA (Health Products Regulatory Authority)

as kalceks - hydromorphone hydrochloride - solution for injection/infusion - hydromorphone

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 50 mg - injection, concentrated - excipient ingredients: sodium chloride; citric acid monohydrate; sodium citrate; water for injections - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: water for injections; sodium chloride; citric acid monohydrate; sodium citrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - hydromorphone hydrochloride, quantity: 10 mg - injection, solution - excipient ingredients: sodium citrate; water for injections; sodium chloride; citric acid monohydrate - for the short-term management of severe pain for which other treatment options have failed, are contraindicated, not tolerated, or are otherwise inappropriate to provide sufficient management of pain.